Erythropoietin treatment in metastatic breast cancer - Effects on Hb, quality of life and need for transfusion

Acta Oncologica

Volumn 41, Issue 6, 2002, Pages 517-524

  Olsson, Anna Maria ^a   Svensson, Jan Henry ^b   Sundström, Judit ^c   Bergström, Stefan ^b   Edekling, Thomas ^d   Carlsson, Göran ^c   Hansen, Jörgen ^b   Svensson, Birgitta ^e   Albertsson, Maria ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Oncology ^*  (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Länshospital Ryhov   (Sweden)

^e Box 47327   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DRUG DOSAGE; HEMOGLOBIN; TUMORS;

ANEMIA; BLOOD TRANSFUSION;

ONCOLOGY;

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUALITY OF LIFE; QUESTIONNAIRE; SAFETY; TIME; TREATMENT INDICATION;

EID: 0346666918     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860214960     Document Type: Article

References (26)

1. Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast. A randomized phase III trial comparing CAF versus VATH alternating with CMFVP: Cancer and Leukemia Group B study 8281. J Clin Oncol 1995; 13: 1443-52.
2. Skillings JR, Sridhar FG, Wong C, Peddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study. Am J Clin Oncol Cancer Trials 1993; 16: 22-5.
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
4. Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer. Acta Oncol 1992; 31: 19-28.
5. Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostata cancer. Eur J Cancer 1997; 33: 1809-14.
6. Wayne W D. Biostatistics: A Foundation for Analysis in the Health Sciences, 6th Ed. New York: John Wiley & Sons, 1995.
7. Montgomery DE. Design and Analysis of Experiments, 3rd Ed. New York: John Wiley & Sons, 1991.
8. The SAS System for Windows. SAS institute Inc., Cary, NC, USA.
9. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161-7.
10. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 332: 1689-92.
11. Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belgica 1996; 51: 36-52.
12. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 1997; 99: 344-51.
13. Means RT, Olsen NJ, Krantz SB, et al. Treatment of anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies. Arthritis Rheum 1989; 32: 638-42.
14. Gudbjörnsson B, Hällgren R, Wide L, et al. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis 1992; 51: 747-52.
15. Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 (Suppl 2): 85-91.
16. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types - Summary and conclusions. Acta Oncol 2001; 40: 135-54.
17. Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001; 40: 175-84 Review.
18. Posner JB. Supportive care in the neuro-oncology patients. In: Hildebrand J, ed. Management in Neuro-oncology. Berlin: Springer-Verlag, 1992: 89-103.
19. Langer CJ. Anemia, Fatigue and Quality of Life in Advanced Malignancy: Potential Therapeutic Role for Epoetin. Erythropoiesis: New Dimensions in the Treatment of Anemia. 1997[il]; 8: 63-73.
20. Glimelius B, Linne T, Hofman K, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998; 16: 434-40.
21. Leitgeb C, Pecherstorfer M, Fritz E, et al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
22. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin (rHuEPO) for the treatment of anemia of cancer. Oncologist 1996; 1: 140-50.
23. Ludwig H, Sundal E, Pechersdorfer M, et al. Recombinant human erythropoietin for the correction of cancer-associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76: 2319-29.
24. Österborg A, Boogaerts MA, Cimina R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study. Vth Int Workshop on Multiple Myeloma. La Boule Sept. 10-13, 1995. Abstract.
25. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: Dose finding and identification of predictors of response. Blood 1995; 86: 4446-53.
26. Pangalis G, Poziopoulos C, Angelopoulou MK, et al. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukemia patients with recombinant human erythropoietin. Br J Haematol 1995; 89: 627-9.